BridgeBio Pharma (BBIO) AI Stock Analysis

• Market Cap: $8.77B
• Dividend Yield: N/A
• Average Volume (3M): 2.97M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: -41.71%
• EPS Growth: -9.37%
• Country: US
• Employees: 725
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.88
• Shares Outstanding: 189,880,720
• 10 Day Avg. Volume: 2,597,558
• 30 Day Avg. Volume: 2,971,368
• PEG Ratio: 0.56
• Price to Book (P/B): -5.42
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -17.47
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 10.67
• Enterprise Value/Gross Profit: 67.90
• Enterprise Value/Ebitda: -4.91
• 1Y Price Target: $63.81
• Price Target Upside: 39.75% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 18

• Rating: 60 Neutral
• Price Target: $44.00 ▼(-3.64%Downside)

BridgeBio Pharma benefits from strong technical momentum and positive earnings call with successful product launches and pipeline progress. However, financial performance and valuation concerns due to unprofitability and high leverage weigh heavily on the overall score.

Positive Factors

Market Growth

The ATTR-CM market is projected to grow to approximately $20B, with unrealized value seen for Attruby, indicating significant growth potential.

Product Launch

The Attruby launch in ATTR-CM is off to a strong start and is expected to exceed expectations, becoming the preferred 1st-line option due to ease of procurement and administration.

Regulatory Approval

The FDA has indicated willingness to grant accelerated approval based on the surrogate biomarker endpoint of αDG glycosylation increase.

Strategic Capital

Royalty monetization provides minimally dilutive capital, increasing strategic flexibility.

Negative Factors

Generic Competition Risk

Pfizer's IP litigation poses a risk, as the outlook could be challenged if Vyndamax goes generic in 2028.

Intellectual Property Litigation

Some discount may be warranted due to uncertainty on long-term outlook caused by competitor PFE's ongoing intellectual property litigation.

BridgeBio Pharma Business Overview & Revenue Model

Company Description

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

How the Company Makes Money

BridgeBio Pharma makes money primarily through the development and commercialization of its pharmaceutical products. The company's revenue model is heavily reliant on advancing its drug candidates through clinical trials and obtaining regulatory approvals for them to be marketed. BridgeBio also enters into collaborations and strategic partnerships with other pharmaceutical companies and research institutions, which can involve milestone payments, licensing fees, and royalties. Additionally, the company may receive funding from investors to support its research and development activities and further expand its drug pipeline. These collaborations and partnerships are crucial as they provide both financial resources and expertise to accelerate the development and potential commercialization of its therapeutic candidates.

BridgeBio Pharma Financial Statement Overview

Summary

BridgeBio Pharma shows strong revenue growth but faces significant challenges in profitability and financial stability, with high leverage and negative equity. Despite improvements in free cash flow, the financial risks remain substantial.

Income Statement

BridgeBio Pharma shows significant revenue growth in the TTM, but remains unprofitable with negative EBIT and EBITDA margins. The gross profit margin is relatively strong at 91.8%, yet the net profit margin is negative, indicating a struggle to convert revenue into profit.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, suggesting high financial leverage and potential insolvency risk. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is also negative, indicating liabilities exceed assets.

Cash Flow

Operating cash flow is negative, but with a slight improvement in free cash flow in the TTM. The ratios of cash flows to net income are not favorable, reflecting ongoing cash burn issues.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	221.90M	9.30M	77.65M	69.72M	8.25M
Gross Profit	218.02M	6.86M	74.21M	66.60M	5.16M
EBITDA	-436.83M	-565.47M	-397.44M	-533.83M	-465.75M
Net Income	-535.76M	-643.20M	-493.96M	-639.30M	-483.93M
Balance Sheet
Total Assets	919.34M	546.38M	623.04M	1.01B	703.59M
Cash, Cash Equivalents and Short-Term Investments	681.10M	434.88M	428.27M	787.51M	607.09M
Total Debt	1.73B	1.74B	1.72B	1.73B	495.79M
Total Liabilities	2.38B	1.89B	1.87B	1.88B	595.70M
Stockholders Equity	-1.46B	-1.35B	-1.25B	-870.41M	57.91M
Cash Flow
Free Cash Flow	-521.66M	-529.03M	-425.81M	-546.18M	-407.23M
Operating Cash Flow	-520.73M	-527.72M	-419.49M	-497.93M	-399.71M
Investing Cash Flow	60.78M	54.03M	453.15M	-200.83M	-52.99M
Financing Cash Flow	748.46M	451.54M	-13.13M	736.45M	447.19M

BridgeBio Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 45.66
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BBIO, the sentiment is Positive. The current price of 45.66 is above the 20-day moving average (MA) of 45.33, above the 50-day MA of 40.40, and above the 200-day MA of 33.15, indicating a bullish trend. The MACD of 1.54 indicates Positive momentum. The RSI at 59.22 is Neutral, neither overbought nor oversold. The STOCH value of 17.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBIO.

BridgeBio Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TGTX	68 Neutral	$5.97B	154.10	19.70%	―	33.54%	-6.13%
Sector *	65 Neutral	¥355.44B	11.10	-2.99%	2.49%	11.76%	-10.16%
LEGN	61 Neutral	$8.14B	―	-20.01%	―	112.54%	54.30%
BBIO	60 Neutral	$8.77B	―	35.68%	―	-41.71%	-9.37%
RVMD	52 Neutral	$6.99B	―	-36.68%	―	-100.00%	5.49%
BPMC	50 Neutral	$8.37B	―	-47.71%	―	99.19%	48.43%
SRPT	47 Neutral	$1.27B	19.61	-23.61%	―	59.15%	-1881.09%

BridgeBio Pharma Corporate Events

BridgeBio Pharma Enters Royalty Purchase Agreement

On June 27, 2025, BridgeBio Pharma, Inc. and its subsidiary Eidos Therapeutics, Inc. entered into a Royalty Interest Purchase and Sale Agreement with Acoramidis Royalty SPV, LP and LSI Financing Fund, LP. Eidos sold certain royalty rights on net sales of products containing acoramidis in the EU to the purchasers for $300 million. This agreement provides BridgeBio with immediate capital while capping the purchasers’ royalty rights and offering security interests in specific assets, potentially impacting the company’s financial strategy and stakeholder interests.

The most recent analyst rating on (BBIO) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.

BridgeBio Pharma Annual Meeting Approves Key Proposals

BridgeBio Pharma held its Annual Meeting on June 20, 2025, where stockholders voted on several key proposals. These included the election of five Class III directors, approval of executive compensation, ratification of Deloitte & Touche LLP as the independent accounting firm, and amendments to the company’s stock option plan and certificate of incorporation. The meeting also approved the adjournment of the meeting if necessary due to insufficient votes.

The most recent analyst rating on (BBIO) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.